Sells KOMZIFTI, an oral medicine for adults with a specific form of leukemia, and develops small-molecule treatments for cancer and other diseases.
10-K for FY2025, filed Mar 5, 20262025 was a pivotal year for our company. On November 13, 2025, the FDA approved our new drug application, or NDA, for ziftomenib, which is…View ↗
We also are exploring the use of KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and…View ↗
In addition to our menin inhibitor programs, we are evaluating farnesyl transferase inhibitors, or FTIs, in combination with various…View ↗
Most revenue comes from collaboration arrangements: partners pay for licensed rights and related work through upfront fees, milestone payments, cost reimbursements and royalties on product sales. In the United States, specialty distributors and pharmacies pay for KOMZIFTI when it is delivered.
10-K for FY2025, filed Mar 5, 2026
10-K for FY2025, filed Mar 5, 2026
FY2025 revenue by product or service ↗$67.5M
10-K for FY2025, filed Mar 5, 2026
$67.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
|
3.2% |
Product revenue, net, FY2025
$2.1M Sources
|
Sold outright |
|
Collaboration Revenue
|
97% |
Collaboration Revenue, FY2025
$65.4M Sources
|
In the United States, specialty distributors and specialty pharmacies buy KOMZIFTI directly, then resell it to pharmacies, health care providers and patients.
10-K for FY2025, filed Mar 5, 2026We sell KOMZIFTI to specialty distributors and specialty pharmacies, our customers in the United States. Our customers subsequently resell…View ↗
No. It lost $278.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$70.2MView ↗
10-Q for Q3 FY2026, filed Nov 10, 2026
Open tableView ↗
8-K, filed Nov 10, 2026
Jennifer Fulk joined Kura in September 2026 as Chief Financial Officer. Ms. Fulk brings more than 20 years of financial and operating…View ↗
8-K, filed Sep 9, 2026
On September 8, 2026, the Company entered into a Contribution and License Agreement (the “Contribution Agreement”) with Caspian, pursuant…View ↗
Commercial launch
The earlier report described clinical product candidates and trials; the latest describes an approved KOMZIFTI and U.S. commercial sales, moving Kura from development into selling a medicine.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.…View ↗
Commercial rights
The earlier report said Kura held global commercial rights to its programs; the latest says Kura and Kyowa Kirin share U.S. commercialization, while Kyowa Kirin handles sales outside the United States.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.…View ↗
Additional disease areas
The earlier pipeline focused on cancer; the latest also describes next-generation menin inhibitors being explored for diabetes and cardiometabolic disorders.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.…View ↗
We also are exploring the use of KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and…View ↗
Competes with Syndax, Janssen, Dainippon Sumitomo, Servier, Biomea Fusion, CHARM Therapeutics, Abbvie, Genentech, Novartis, Astellas, BMS, Rigel, Daiichi-Sankyo, Merck, AstraZeneca, Exelixis, Eisai, Amgen, and Mirati
10-K for FY2025, filed Mar 5, 2026We are aware of other companies with competing commercial or clinical-stage menin inhibitor programs, including Syndax, Janssen (Johnson &…View ↗
Loading...